Rimegepant for Migraine: Effects on Obesity

We are studying how rimegepant affects migraine-related reactions in lean and obese individuals. The goal is to understand the relationship between body composition and migraine responses.

6-12 months ≤5 visits Monitoring phase (IV)No Placebo Cost Reimbursement Standard Medicines OralEndocrinologyNeurology

What diseases are being studied?

Health conditions and diseases that the clinical trial is designed to study and treat.

Who can participate in the clinical trial?

These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..

What active substances are being studied?

Active substances that are officially approved for use in the European Union and considered safe by EMA. These substances are already on the market and may be tested for new conditions or populations.

Capsaicin

Capsaicin is a substance used topically to relieve nerve-related pain by reducing local nerve sensitivity.

Rimegepant

Rimegepant is a substance used to treat and help prevent migraine headaches.

Where is the clinical trial being conducted?

Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.

Loading map...

Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)

Internal Medicine

Rotterdam, Netherlands

Sponsor: Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)

Last updated: Nov 27, 2025

Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.